ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BOLD Boundless Bio Inc

10.09
-1.21 (-10.71%)
Apr 19 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 160,267
Bid Price 5.00
Ask Price 11.25
News -
Day High 11.50

Low
9.94

52 Week Range

High
15.20

Day Low 9.94
Company Name Stock Ticker Symbol Market Type
Boundless Bio Inc BOLD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-1.21 -10.71% 10.09 19:30:40
Open Price Low Price High Price Close Price Prev Close
11.50 9.94 11.50 10.09 11.30
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,640 160,267 $ 10.45 $ 1,674,151 - 9.94 - 15.20
Last Trade Time Type Quantity Stock Price Currency
16:00:00 10,681 $ 10.09 USD

Boundless Bio Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
3.15B 311.79M - 0 -49.43M -0.16 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Boundless Bio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BOLD Message Board. Create One! See More Posts on BOLD Message Board See More Message Board Posts

Historical BOLD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week11.5011.90089.9411.05112,938-1.41-12.26%
1 Month14.2515.209.9412.92268,719-4.16-29.19%
3 Months14.2515.209.9412.92268,719-4.16-29.19%
6 Months14.2515.209.9412.92268,719-4.16-29.19%
1 Year14.2515.209.9412.92268,719-4.16-29.19%
3 Years14.2515.209.9412.92268,719-4.16-29.19%
5 Years39.7660.009.9446.31679,198-29.67-74.62%

Boundless Bio Description

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.

Your Recent History

Delayed Upgrade Clock